Digoxin: Use pattern in Estonia and bioavailability of the local market leader

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 5, 1999, Pages 375-380

  Pahkla R ^b   Irs, A ^c   Oselin, K ^c   Rootslane, L ^a  

^a State Agency of Medicines   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GENERIC DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMOLUMINESCENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGOXIN BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; DRUG USE; ESTONIA; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VOLUNTEER;

ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CARDIOTONIC AGENTS; CROSS-OVER STUDIES; DIGOXIN; DRUG UTILIZATION; ESTONIA; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD; THERAPEUTIC EQUIVALENCY;

EID: 0032708390     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00239.x     Document Type: Article

References (22)

1. 1. van Veldhuisen DJ, de Graeff PA, Remme WJ, Lie KJ. (1996) Value of digoxin in heart failure and sinus rhythm: new features of an old drug? Journal of American College of Cardiology, 28, 813-819.
2. 2. Williamson KM, Patterson JH. (1997) Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? A protagonist viewpoint. Annals of Pharmacotherapy, 31, 888-892.
3. 3. Adams KF, Gheorghiade M, Uretsky BF, et al. (1998) Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. American Heart Journal, 135, 389-397.
4. 4. Pfammater JP, Stocker FP. (1998) Re-entrant supra-ventricular tachycardia in infancy: current role of prophylactic digoxin treatment. European Journal of Pediatrics, 157, 101-106.
5. 5. Tunock Y, Hazan E, Oto O, Guven H, Catalyurek H, Kalkan S. (1997) Relationship between high serum digoxin levels and toxicity. International Journal of Clinical Pharmacology and Therapeutics, 35, 366-368.
6. 6. Ordog GJ, Benaron S, Bhasin V, Wasserberger J, Balasubramanium S. (1987) Serum digoxin levels and mortality in 5100 patients. Annals of Emergency Medicine, 16, 32-39.
7. 7. Martín-Suárez A, Lanao JM, Calvo MV, Martin P, Domínguez-Gil A. (1993) Digoxin pharmacokinetics in patients with high serum digoxin concentrations. Journal of Clinical Pharmacy and Therapeutics, 18, 63-68.
8. 8. Dobbs RJ, Royston JP, O'Neill CJ, et al. (1987) Prescribing digoxin in geriatric units: the unexplained variability in dosage requirements. European Journal of Clinical Pharmacology, 32, 611-614.
9. 9. Beveridge T, Kalberger F, Nüesch E, Schmidt R. (1975) Bioavailability studies with Digoxin-Sandoz® and Lanoxin®. European Journal of Clinical Pharmacology, 8, 371-376.
10. 10. Lindenbaum J, Mellow MH, Blackstone MO, Butler VP Jr. (1971) Variation in biologic availability of digoxin from four preparations. New England Journal of Medicine, 285, 1344-1347.
11. 11. Huffman DH, Azarnoff DL. (1972) Absorption of orally given digoxin preparations. Journal of the American Medical Association, 222, 957-961.
12. 12. Wagner JG, Christensen M, Skamar E, et al. (1973) Equivalence lack in digoxin plasma levels. Journal of the American Medical Association, 224, 199-204.
13. 13. Anon. (1997) Svensk Läkemedelsstatistic. Stockholm: Apoteksbolaget.
14. 14. Oydvin K, ed. (1998) Drug Consumption in Norway 1993-97. Oslo: Norsk Medisinaldepot AS.
15. 15. Anon. (1998) Finnish Statistics on Medicines. Helsinki: National Agency for Medicines.
16. 16. Kiivet RA, Bergman U, Rootslane L, Rägo L, Sjöqvist F. (1998) Drug use in Estonia in 1994-95: a follow-up from 1989 and comparison with two Nordic countries. European Journal of Clinical Pharmacology, 54, 119-124.
17. 17. Mooradian AD. (1988) Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clinical Pharmacokinetics, 15, 165-179.
18. 18. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW. (1976) Assessment of methodology in single-dose studies of digoxin bioavailability. Pharmacology, 14, 182-190.
19. c) and importance of blood and urine sampling scheme with application to digoxin. Journal of Pharmacokinetics and Biopharmaceutics, 5, 533-557.
20. 20. Ochs HR, Bodem G, Greenblatt DJ. (1981) Effect of dose on bioavailability of oral digoxin. European Journal of Clinical Pharmacology, 19, 53-55.
21. 21. Fowle AS, French J, O'Grady J. (1981) The effects of some organic solvents on the absorption of digoxin by man. Arzneimittelforschung, 31, 1029-1031.
22. 22. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW. (1974) Comparison of one- and six-day urinary digoxin excretion in single-dose bioavailability studies. Clinical Pharmacology and Therapeutics, 16, 813-816.